As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: March 26, 2014
by Business Standard:
Scientists have developed a test that could predict the risk of developing Alzheimer’s disease by detecting abnormalities in spinal fluid.
The test detects tiny, misfolded protein fragments called beta amyloid oligomers in cerebrospinal fluid taken from patients. Scientists used to think amyloid plaques were the problem in Alzheimer’s disease.
“Now it seems clear that the aggregates are not the main culprits, it’s their precursors, so-called beta amyloid oligomers,” said Claudio Soto of the University of Texas Medical School at Houston.
“This is the key molecule and could be the best, most reliable way to make an early diagnosis,” Soto said. “Those beta amyloid oligomers may be circulating in the body for years if not decades before cognitive symptoms arise,” Soto added.
In the new study, Soto and his colleagues applied a technology they developed earlier for detection of the misfolded proteins responsible for prion diseases including mad cow disease.
Their protein misfolding cyclic amplification (PMCA) technology works by amplifying existing misfolded proteins and then breaking them up into smaller pieces.
When mixed with the equivalent, normal protein, the misfolded fragments act as seeds for the formation, in the case of beta amyloid, of amyloid clumps like those found in the Alzheimer’s brain.
The researchers showed that their PMCA technology can detect beta amyloid oligomers at incredibly low concentrations.
In principle, their earlier prion work suggests it might be possible to detect even a single particle of misfolded beta amyloid.
Most importantly, Soto and his colleagues were able to distinguish between patients with Alzheimer’s disease and those with other neurodegenerative or neurological disorders with 90 per cent sensitivity and 92 per cent specificity by applying their test to cerebrospinal fluid samples.
The next step, Soto said, is to adapt the technology for use with blood or urine samples, which would be much easier to obtain for screening perfectly healthy people for biochemical signs of Alzheimer’s disease.
If additional research can confirm the utility of the test in Alzheimer’s and perhaps other conditions (eg Parkinson’s disease), Soto said a US Food and Drug Administration-approved test could be on the market in as little as three years.
The findings were reported in the Cell Press journal Cell Reports.
Consumption of canola oil is linked to weight gain and declines in memory and learning ability in mice that model Alzheimer’s disease, according to a new study published in the journal Scientific Reports. Canola...
Low memory scores are an early marker of amyloid positivity, but have limited value as a screening measure for early Alzheimer’s disease among persons without dementia, according to a study published online in JAMA Psychiatry. Willemijn J....
Can the brain heal and preserve itself—or even improve its functioning—as we get older? For some time, many scientists have tended to think of our brains as machines, most commonly as computers,...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.